PRM48 The Half-Cycle “Correction”: How Much of a Correction is it?  by Taylor, M. & Lewis, L.
come countries. METHODS: We systematically reviewed the literature on the ap-
plication of CVD risk models in pharmacoeconomic studies. We assessed the qual-
ity of incorporation of risk models in these studies by evaluating the agreement of
the population characteristics and the time horizon applied between the risk
model and the pharmacoeconomic study, the appropriateness of the risk model for
the population studied, and the incorporation of the uncertainty of the risk model
in the sensitivity analysis. RESULTS: We identified 12 studies using published CVD
risk models. The studies demonstrated the usefulness of projecting intermediate
effectiveness endpoints to long term, health and cost related, benefits. However,
our quality assessment highlighted the distance between the populations of the
risk model and the studies reviewed, the disagreement between risk model and
study time horizons, and the lack of consideration of all uncertainty surrounding
risk predictions. CONCLUSIONS: Given that utilizing a risk model to project the
effect of a pharmacological intervention to CVD events provides an estimate of the
intervention’s clinical and economic impact, consideration should be paid on the
agreement between the study and risk model populations as well as the level of
uncertainty that these predictions add to the decision-analytic model. In the ab-
sence of hard endpoint trials, the value of risk models to model pharmacological
efficacy in primary CVD prevention remains high, although their limitation should
be acknowledged.
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OBJECTIVES: In developed countries mortality in the general population has been
declining for several decades and is anticipated to decrease further, especially
among the elderly. Life tables based on national statistics reflect mortality condi-
tions of a particular year and therefore do not take into account that survival
increases in the general population. As a consequence, life tables seem to system-
atically underestimate overall survival of the general population. Health economic
models use life tables to predict survival of the general population and may there-
fore also underestimate survival. Our study compares survival prediction methods
and discuss implications for health economic models. METHODS: Period life ex-
pectancy at age 50 calculated from Dutch mortality rates published for 2009 was
compared with life expectancy of a cohort aged 50 in 2009 calculated from pro-
jected mortality rates forecasted by the standard Lee-Carter approach. The Lee-
Carter model forecasts the level and age pattern of mortality based on the combi-
nation of singular value decomposition of mortality rates and statistical time series
methods. Mortality rates were taken from the Human Mortality Database. Projec-
tions were based on historical data between 1970 and 2009. RESULTS: Based on
projected mortality, cohort life expectancy was 34.97 years whereas period life
expectancy was only 32.37 years (2.60 years). When life years were discounted at
a 1.5% rate, the corresponding values were 25.31 and 26.40 years (1.09 years).
CONCLUSIONS: The analyses shows that taking into account the decrease in sur-
vival over time results in a difference of 7% in undiscounted and 4% in discounted
life expectancy in the Netherlands. This difference can have a substantial impact
on cost-effectiveness results, especially of curative interventions for diseases that
are life threatening or of prevention programmes over a long time horizon. In these
cases, sensitivity analysis should be carried out to investigate the impact of de-
creasing mortality.
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OBJECTIVES: The NICE reference case stipulates cost-utility analysis as the pre-
ferred form of economic evaluation, with health effects expressed in QALYs and
health states valued using a validated choice-based method such as the time-
trade-off (TTO). The evidence-base describing the impact of visual impairment (VI)
on quality-of-life is very limited. To date, the Czoski-Murray et al. (2009) utility
values for 4 visual health severity groups are considered the most plausible set of
utility values for use in eye-disorder economic models. These utility values, origi-
nally elicited through simulating VI similar to that associated with wet age-related
macular degeneration, were recently applied in other retinal disorders such as
diabetic macular edema. The objective of our analysis was to refine the mapping of
utilities onto visual acuity (VA). METHODS: OLS regression models were built to
estimate the relationship between mid-point VA of 4 visual health severity groups
and mean TTO scores as described in the literature. Linear and non-linear ap-
proaches for utility estimation as a function of the number of VA letters were
explored. RESULTS: The linear regression for utility estimation was found to be
statistically significant. The beta-coefficient for mid-point VA was 0.0054 (p0.030)
and 0.2864 for the constant term (p0.034). Linear regression estimates were used
to predict the utility value for 6 pre-specified VA health states: VA1 (0.766); VA2
(0.671); VA3 (0.616); VA4 (0.562); VA5 (0.507); VA6 (0.382). CONCLUSIONS: Published
evidence on utility values for deterministic visual health severity groups may not
easily transpose to alternative vision health-states. Our analysis demonstrated an
original approach for utility estimation allowing a more flexible and robust method
to map previously elicited VA-associated utilities onto alternate VA health-states.
This method allows wider applicability of VA-associated utility estimation in other
eye disorders characterized by VA impairment such as vitreomacular traction and
macular hole.
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OBJECTIVES: Dynamical processes in cost-effectiveness analysis (CEA) are typi-
cally described using Markov models that account for the full stochastic nature of
the process, or alternatively using systems of ordinary differential equations
(ODEs). In CEAs, ODEs are useful for defining dynamical systems with complex,
time-varying properties that often need to be considered, and are difficult to im-
plement as Markov models. However, in the field of CEA, fixed step sizes (‘cycle
lengths’) are used for solving systems of ODEs, which may result in bias if the step
size is too large in relation to the magnitude of change. The aim of this project was
to implement and demonstrate the use of a well established dynamical ODE solver
algorithm (LSODA) for CEAs in the statistical scripting language R, and to quantify
bias in outcome caused by use of a fixed-step size cohort simulation approach.
METHODS: To demonstrate the proposed approach, a previously reported CEA on
adjuvant breast cancer therapies was re-analysed using the ODE solver algorithm
LSODA. A model implementing the fixed-cycle length method was also developed
to compare bias by using a range of different cycle lengths. RESULTS: The CEA
model was successfully developed using the ODE solver LSODA. The use of fixed
cycle lengths resulted in bias compared to the outcome of the ODE model. A cycle
length of 1 year resulted in an underestimation of 0.016 absolute LYs (5.6%) and
€158 (6.8%) compared to the dynamical-step size model. CONCLUSIONS: The de-
veloped dynamical approach was found to be suitable for conduct of CEA’s and
flexible in use. Moreover, it was demonstrated that use of fixed cycle lengths could
potentially cause unnecessary bias in CEA outcomes. Finally, we advocate use of
scripting languages such as R in the field of health economics to improve transpar-
ency, reproducibility and overall integrity of conducted CEAs.
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OBJECTIVES: To compare cost-effectiveness model input influence on incremental
net monetary benefit (INMB) across three methods of uncertainty analysis: 1) one-
way sensitivity analysis; 2) probabilistic analysis of covariance (ANCOVA); and 3)
expected value of partial perfect information (EVPPI). METHODS: We replicated
and expanded a published HIV/AIDS cost-effectiveness Markov model (mono-
therapy vs. combination therapy) using TreeAge®. Case 1 assumed a willingness-
to-pay of £20,000/QALY (relatively low decision uncertainty in this application).
Case 2 assumed a willingness-to-pay of £8,000/QALY (relatively high decision un-
certainty). For Cases 1 and 2, one-way sensitivity analysis identified the ten most
influential inputs. From these ten inputs, we estimated ANCOVA results (10,000
Monte Carlo draws) and EVPPI for each input (1,000 inner and 1,000 outer draws).
For each case and method, we ranked inputs based on their influence on variation
of INMB and compared input ranks within case using Spearman’s rank correlation.
RESULTS:Mean INMB was £9,740 (Case 1) and £179 (Case 2) in favor of combination
therapy. Case 1: The two most influential inputs were the same across all uncer-
tainty methods, contributed 78% of variation in outcome (ANCOVA), and were the
only inputs with non-zero EVPPI values. Case 2: All inputs had non-zero EVPPI
values, with the two most influential inputs accounting for 49% of variation in
outcome (ANCOVA). For Cases 1 and 2, the influential input rank order correlations
across uncertainty methods ranged from 0.70 to 0.99 (all p-values  0.05 for pair-
wise uncertainty method correlations for both cases). CONCLUSIONS: For both
cases, the influential input ranks were positively correlated between one-way and
more advanced uncertainty analyses, indicating influential input rank agreement.
Although each method provides unique information, the additional resources
needed to generate and communicate advanced analyses should be weighed, es-
pecially when the outcome decision uncertainty and therefore value of informa-
tion is low. (i.e. Case 1).
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OBJECTIVES: In economic models that use Markov-type processes, it is generally
recommended that a ‘half-cycle correction’ be built into the analysis, to account for
the fact that events can occur at any point during the cycle. This study explores the
implications of the half-cycle correction, and highlights a number of flaws in the
approach. METHODS: A brief review of health technology assessment models was
undertaken to determine the use of half-cycle corrections. The study aimed to
explore the theoretical, practical and mathematical implications of the half-cycle
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correction. A simple Markov model was built to illustrate the impact of the half-
cycle correction, and to demonstrate how a more accurate correction factor can be
applied to models. RESULTS: Half-cycle corrections appear to be used routinely in
Markov models. In nearly all cases, the so-called “correction” is applied without
due consideration of the implications. Two major flaws were identified with the
approach. The first, mathematical, flaw is that the half-cycle correction approach
assumes that all events occur at the mid-point of each cycle. It can be demon-
strated that, for one-directional events (such as death), events will be more likely to
occur in the first half of the cycle since more patients will be exposed to the event
at the start of the cycle, and the number of patients ‘at risk’ falls throughout the
cycle. The second flaw is that, for many events, the implications of the event may
not actually become apparent until the next cycle. For instance, in oncology, the
increased costs associated with disease progression will not occur until progres-
sion is confirmed, which may only happen at regular routine follow-up visits.
CONCLUSIONS: Half-cycle corrections are frequently applied inappropriately in
modelling. This study has produced two key recommendations to generate more
accurate outcomes and to avoid biases in decision analytic models.
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OBJECTIVES: To define the extent to which using the EQ-5D versus disease-specific
instruments is critical in overall cost-effectiveness assessments, specifically re-
garding cost-utility. METHODS: Five ISPOR therapeutic areas (TAs) were randomly
selected, and literature research found on PubMed for the UK, as well as other
European publications, to retrieve publically available data on health state utility
scores in the respective TAs. Data were extracted into a database and various
model structures reconstructed in order to determine the impact of different HR-
QoL instruments on overall cost-effectiveness. Standard Monte Carlo techniques
were applied to generate simulations, informing both the expected cost-effective-
ness and its associated uncertainty. Cost-utility as well as net monetary / health
benefit were considered, based on willingness-to-pay for a QALY values ranging
from zero to €100,000. Incremental cost-utility scatter-plots as well as cost-effec-
tiveness acceptability curves were generated to illustrate how the results differ
both deterministically and probabilistically. RESULTS: The mean percentage
change in the cost-utility ratio across all five disease areas was app. 29% (a 95%
confidence interval ranging from21% to42%). Similar but even stronger results
were found when using incremental net monetary benefit measures. The thera-
peutic area with the most significant difference was oncology (36.5%), and the least
significant was cardiovascular (19%). Other TAs were COPD, Parkinson’s disease,
and obesity. CONCLUSIONS: It was consistently found that cost-effectiveness re-
sults differed significantly when different HR-QoL measures were used. Since dis-
ease-specific instruments employ more sensitive criteria than generic ones, they
generate more favourable cost-effectiveness results. Comparing the results of both
generic and specific indicators in structural sensitivity analyses appears to be im-
perative to assess the consistency of value judgements derived from quantitative
modelling.
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OBJECTIVES: Monte Carlo simulations are driven by the generation of pseudo ran-
dom numbers (PRN). Testing the effectiveness of PRN generators is rarely under-
taken yet any systematic pattern or bias has implications for simulation run time
and accuracy. The objective of this study was to compare two commonly used PRN
in an applied setting to illustrate potential implications of low performance.
METHODS: The IMS Core Diabetes Model (CDM) was used to explore their precision
in detecting the onset of end stage renal disease (ESRD using the MS-Visual C
2008 PRN generator (MSG) and Mersenne Twister generator (MTG). One-year prob-
abilities of ESRD for a 65 year old female smoker were generated with a systolic
blood pressure (SBP) of 135 mmHG (p0.000363) and 140 mmHg (p0.000444). The
expected one-year incidence was compared to probabilistic observations in the
CDM for both PRN generators. RESULTS: The expected yearly incidence of ESRD
was 0.0363% (SBP 135 mmHg) and 0.0444% (SBP (140mmHG). Monte Carlo estimates
were 0.0379% and 0.0477% using the MSG and 0.0239% for both SBP values using the
MTG. The MSG overestimated expected rates by 4.41% and 7.4%; the MTG under-
estimated the probability of ESRD by 34.16% and 46.17% SBP for 135mmHG and
140mmHg, respectively. The deterministic relative increase in incidence of ESRD
(22.3%) associated with a 5mmHg increment in SBP was similar to the MSG (25.8%);
using the MTG resulted in a 0% increase in the probability of ESRD. Analysis of the
frequency distribution of the MTG displayed areas sparsely populated with random
variates. CONCLUSIONS: The two PRN generators tested in this analysis produced
substantially different results. The differences between the two PRN algorithms
were most apparent when predicting relatively rare events, such ESRD. When as-
sessing the internal validity of Monte Carlo simulations the efficieny and robust-
ness of PRN generators should not be assumed.
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OBJECTIVES: In health economic modeling the role of probabilistic sensitivity anal-
ysis (PSA) is to assess the uncertainty of model predictions with respect to the
underlying parameter uncertainty. However, in Monte Carlo simulation parameter
uncertainty coincides with and cannot be distinguished from random noise, Monte
Carlo error (MCE). The objective of this study was to quantify the minimum run
time requirements to reduce MCE to acceptable levels. METHODS: An established
and validated model, the IMS CORE diabetes model (CDM), was used to compare
outcome variability of bootstrap simulations with 1000 repetitions and increasing
number of patients ranging from 2500 to 100000. Model projections were defined to
evaluate the cost effectiveness of two hypothetical interventions with differences
in clinical effectiveness of 0.5% HbA1c and a 2kg weight change in favor of the
treatment vs. control arm. Each simulation was performed in three ways; 1st where
no parameter sampling was applied, 2nd and 3rd where parameters were sampled
around 5% (SE based PSA) and 25% (SD based PSA) of their mean values, respec-
tively. The degree of MCE was determined according to the ratio of the confidence
ranges (ICER per QALY) of the non sampling analyses versus PSA. RESULTS: The
proportion of Monte Carlo error contained in overall ICER variability for simula-
tions with increasing number of patients (2500, 5000, 10000, 25000, 50000 and
100000) was found at 110%, 107%, 73%, 54%, 45% and 32% for SE based PSA and 80%,
80%, 37%, 13%, 9%, and 6% for SD based PSA. CONCLUSIONS: Run time require-
ments to reduce MCE are lower whenever the uncertainty of included parameters
is increased. Hypothesizing that not more than 40% of overall outcome variability
should be attributable to MCE, the minimum run time requirement was found at
100000 and 10000 patients for SE and SD based PSA, respectively.
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OBJECTIVES: The use of rhinitis total symptom scores (RTSS) is the recommended
method for documenting clinical effect of interventions in allergic rhinitis and
conjunctivitis. For cost utility analysis a patient preference measure (health state
utility) is needed. We explore whether the disutility of allergic rhinitis can be esti-
mated from RTSS. METHODS: We explored the properties of the RTSS and com-
pared these to the properties of the Rhinitis Symptoms Utility Index (RSUI) - a
multi-attribute utility function of rhinitis health states. Furthermore, we simulated
the outcome of a 2 week period with allergic rhinitis and compared the variation in
RSUI associated with each RTSS score to minimal important difference (MID) for
utility.RESULTS:RTSS is a linear mapping of daily reported rhinitis symptoms with
respect to frequency, type, and severity of symptoms. RSUI is multiplicative map-
ping of frequency, type and severity. This makes the RSUI a non-monotone map-
ping of RTSS which rules out direct one-to-one mapping from RTSS score to RSUI
utility score. The simulation showed that a specific RTSS score can result in very
different RSUI values; e.g. a RTSS score of 2.21 (fairly low symptom load) can be
associated with a RSUI in the range from 0.376 to 0.784. Since the span of possible
RSUI associated with each RTSS score is larger than the MID for utility by any
standards, no approximated mapping is not possible without making further as-
sumption on type of symptoms. CONCLUSIONS: The RTSS is a standard, recom-
mended measure of clinical effect in rhinitis and conjunctivitis intervention stud-
ies; however, further research is needed before patient health state preferences
and utility gains from interventions can be estimated from RTSS. These findings
emphasize the importance of using validated methods/tools when estimating and
comparing utility gains from separate interventions.
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OBJECTIVES: The use of patient level data (PLD) within cost-effectiveness models
offers the potential to analyse the relationship between individual input profiles
and predicted output. The objective of this study was to ascertain if particular PLD
input profiles were predictive of cost effectiveness sub-groups in Type 2 diabetes
mellitus (T2DM) subjects.METHODS: This study used the IMS Core Diabetes Model
(CDM), a validated and established diabetes model to evaluate the cost effective-
ness of a new 2ndline oral therapy (Treatment) compared to metformin sulpho-
nylurea (Control). Delta treatment effects (favouring Treatment) were a 0.5% HbA1c
reduction, 2kg weight change and a difference in symptomatic hypoglycaemia of
0.9/100 patient years. Annual diabetes specific therapy cost was £455 (Treatment)
versus £70 (Control). A PLD extract was obtained from NHANES over the period of
1999 to 2008 of T2DM subjects treated with oral therapy only. Costs (2010 UK£) and
benefits were discounted at 3.5%. Analysis of input/output data was undertaken
using R. RESULTS: PLD for 1,858 T2DM subjects from NHANES were obtained with
mean age 63.6 years of which 53% were male. Mean estimated cost per QALY of
Treatment versus Control was £6,111. Multivariate logistic regression identified age
(p0.05), SBP (p0.001) and HbA1c (p0.001) as model input variables significantly
associated with cost effectiveness at a willingness to pay (WTP) threshold of
£20,000. HbA1c was linearly and negatively correlated with incremental cost
(£569 per 1% increase (p0.001)). Subjects with baseline HbA1c7.4% had signif-
icantly lower incremental costs compared to those £ 7.4% (£ 1,205 versus £3,462
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